問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol Number300383
Not yet recruiting

2025-10-01 - 2029-06-30

Phase III

Recruiting6

ICD-10C16.0

Malignant neoplasm of cardia

ICD-10C7A.092

Malignant carcinoid tumor of the stomach

ICD-10Z51.12

Encounter for antineoplastic immunotherapy

ICD-9151.0

Malignant neoplasm of cardia of stomach

  • Trial Applicant

    GlaxoSmithKline

  • Sponsor

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2026/02/01

Investigators and Locations

Principal Investigator Chueh-Chuan Yen Division of Others -

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Li-Tzong Chen Digestive System Department

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 陳彥仰 Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 曾若涵 Division of Hematology & Oncology

Co-Principal Investigator

  • 石宇閎 Division of Hematology & Oncology
  • 王全正 Division of Hematology & Oncology
  • 林正純 Division of Hematology & Oncology
  • 張維容 Division of Gastroenterological Surgery
  • 賴冠銘 Division of Hematology & Oncology
  • 黃晟維 Division of Hematology & Oncology
  • 林國華 Division of Gastroenterological Surgery
  • 張宏基 Division of Gastroenterological Surgery
  • 林炫聿 Division of Hematology & Oncology

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Kun-Huei Yeh Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Chun-Nan Yeh Division of General Surgery

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Condition/Disease

Objectives

Test Drug

Active Ingredient

Dosage Form

Dosage

Endpoints

Inclution Criteria

The Estimated Number of Participants

  • Taiwan

    14-20 participants

  • Global

    450 participants